SCHEMBL6160716

SCHEMBL6160716

CC(C)(C)NC(=O)Oc1cccc(O)c1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.61
ESR1 P03372 2/20 0.50
ESR2 Q92731 2/20 0.50
POLB P06746 1/20 0.46
TRPV1 Q8NER1 1/20 0.41
FAAH O00519 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPK1 P28482 1/20 0.41
ALPL P05186 1/20 0.41
ALPI P09923 1/20 0.41
ALPG P10696 1/20 0.41
BCHE P06276 2/20 0.41
ACHE P22303 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28981602 0.85 ESR1 (0.49) ESR1ESR2ALDH1A1MAPK1BCHE
SCHEMBL27541469 0.83 KMT2A (0.59) CYP3A4ALDH1A1NPC1RAB9ANPSR1
SCHEMBL27691335 0.83 NPC1 (0.48) CYP3A4ESR1ESR2NPC1RAB9A
SCHEMBL28038148 0.83 CYP3A4 (0.41) CYP3A4FAAHALDH1A1MAPK1BCHE
SCHEMBL11798709 0.83 FAAH (0.49) CYP3A4POLBTRPV1FAAHALDH1A1
SCHEMBL27753771 0.83 TBXA2R (0.44) CYP3A4FAAHALDH1A1MAPK1BCHE
SCHEMBL27391395 0.83 CYP3A4 (0.46) CYP3A4FAAHALDH1A1MAPK1BCHE
SCHEMBL10971933 0.82 CYP3A4 (0.65) CYP3A4ESR1ESR2POLBALDH1A1
SCHEMBL21357271 0.82 CYP1A2 (0.56) CYP3A4ALDH1A1MAPK1NPC1RAB9A
SCHEMBL27864672 0.82 CYP3A4 (0.48) CYP3A4FAAHALDH1A1MAPK1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115353466-B Preparation and purification method of neostigmine methosulfate 云南先施药业有限公司 2023-08-01 CN disclosed
CN-116082193-A Preparation and purification method of neostigmine methosulfate 云南先施药业有限公司 2023-05-09 CN disclosed
CN-108047142-B Heteroaryl compounds and uses thereof 西建卡尔有限责任公司 2021-08-03 CN disclosed
CN-110177795-A Prepare the new method and intermediate of Thienopyrimidine compound 韩美药品株式会社 2019-08-27 CN disclosed
CN-109563073-A For the treatment of para-5-HT1AReceptor-controlled serotonergic disease-modulating compounds 诺罗利西斯公司 2019-04-02 CN disclosed
CN-109476699-A Glucocorticoid receptor agonist and its immune conjugate 艾伯维公司 2019-03-15 CN disclosed
CN-108137614-A A kind of condensed pyramidine compounds and composition comprising the compound and application thereof 深圳市塔吉瑞生物医药有限公司 2018-06-08 CN disclosed
CN-108047142-A Heteroaryl compound and its purposes 阿维拉制药公司 2018-05-18 CN disclosed
CN-106146407-A Heteroaryl compound and its purposes 阿维拉制药公司 2016-11-23 CN disclosed
CN-102740847-B Heteroaryl compounds and uses thereof 阿维拉制药公司 2016-06-29 CN disclosed
CN-102656142-A Substituted benzenesulfonamides BAYER SCHERING PHARMA AG 2012-09-05 CN disclosed
CN-102083800-A Heteroaryl compounds and uses thereof AVILA THERAPEUTICS AND USES TH 2011-06-01 CN disclosed
CN-102036952-A Bis-aryl compounds for use as medicaments BIOLIPOX AB 2011-04-27 CN disclosed
EP-1226119-B1 TYROSINE KINASE INHIBITORS MERCK & CO INC (US) 2005-03-16 EP disclosed
CN-1162427-C Amine derivatives compounds ������������ʽ���� 2004-08-18 CN disclosed
EP-1226119-A4 TYROSINE KINASE INHIBITORS MERCK & CO INC (US) 2003-04-09 EP disclosed
US-6479512-B1 TO TREAT TYROSINE KINASE-DEPENDENT DISEASES AND CONDITIONS, SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, ETC. MERCK & CO., INC. 2002-11-12 US disclosed
EP-1226119-A2 TYROSINE KINASE INHIBITORS MERCK & CO. INC. (US) 2002-07-31 EP disclosed
CN-1354750-A Amine derivatives compounds SANKYO CO (JP) 2002-06-19 CN disclosed
WO-2001028993-A2 TYROSINE KINASE INHIBITORS MERCK & CO. INC. (US) 2001-04-26 WO disclosed